comparemela.com

Latest Breaking News On - Pandemic special access route - Page 3 : comparemela.com

MSD obtains Singapore HSA interim authorisation for Covid-19 antiviral

MSD has obtained interim authorisation from Singapore HSA for its antiviral medicine Lagevrio (molnupiravir) to treat Covid-19.

United-states
Singapore
America
Singapore-health-sciences-authority
Company-news
Medicines-advisory-committee
Ministry-of-health
North-america
Pandemic-special-access-route

Oral antiviral molnupiravir gets interim authorisation for Covid-19 treatment in S'pore

It will be prescribed and prioritised for those at higher risk of severe illness. . Read more at straitstimes.com.

Canada
United-states
Singapore
Ridgeback-biotherapeutics
Singapore-health-sciences-authority
Pandemic-special-access-route
Health-sciences-authority
Miami-based-ridgeback

HSA says Singapore's Covid-19 test kits under brands in FDA's warning are not affected

The US Food and Drug Administration (FDA) had on Tuesday (March 1) issued an advisory warning people not to use the SD Biosensor Inc. STANDARD Q Covid-19 Ag Home Test. On its website, the FDA explained that it is concerned about the risk of false results when using this test. It advised those who have used the test kit and.

Singapore
Singaporeans
Biosensor-covid
Paul-tambyah
Health-sciences-authority
Asia-pacific-society-of-clinical-microbiology
Drug-administration
Sd-biosensor-inc
Antigen-rapid-test
Home-test
Home-tests
Asia-pacific-society

Covid-19 vaccine Novavax approved for those aged 18 and above

SINGAPORE - The Covid-19 vaccine developed by Novavax has been approved for individuals aged 18 and above, said the Health Sciences Authority (HSA) on Monday (Feb 14). HSA had granted interim authorisation for Nuvaxovid vaccine on Feb 3, 2022 under the Pandemic Special Access Route (PSAR). The vaccination regimen comprises two five-microgram doses of Nuvaxovid to be administered 3 weeks.

Singapore
Panel-of-infectious-diseases-experts
Pfizer
Medicines-advisory-committee
Health-sciences-authority
Pandemic-special-access-route
Advisory-committee
Infectious-diseases-experts

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.